
[0036] In some embodiments, CyC is C_{3-6}cycloalkyl selected from monocyclic C_{3-8}cycloalkyl or bridged cycloalkyl (), each of which is optionally substituted with one or two substituents R^{3a}.

[0037] In some embodiments, CyC is cyclobutyl, cyclopentyl or cyclohexyl, each of which is optionally substituted with one or two substituents R^{3a}.

[0038] In some embodiments, CyC is:

a) heterocyclyl selected from monocyclic 4 to 9-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as ring member; monocyclic 4 to 9-membered heterocyclyl groups containing two heteroatoms selected from oxygen, sulfur, and nitrogen as ring members,

b) 5 to 10-membered spiro heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, or,

c) 5 to 10-membered bridged heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members;

each of which is optionally substituted with one, two, three or four substituents R^{3a}.

[0039] In some embodiments, CyC is monocyclic 4 to 6-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as the ring members.

[0040] In some embodiments, Cyc is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperidinyl.



[0041] In some embodiments, CyC is selected from oxetan-2-yl, Oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl, piperidin-2-yl, and piperidin-3-yl.

[0042] In some embodiments, CyC is a monocyclic 6-membered heterocyclyl group containing two heteroatoms selected from oxygen and nitrogen as ring members.

[0043] In some embodiments, CyC is dioxanyl, morpholino, morpholinyl, or piperzinyl.

[0044] In some embodiments, CyC is 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.

[0045] In some embodiments, CyC is 4-membered/4-membered, 3-membered/5-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro heterocyclyl comprising one or two nitrogen or oxygen as ring members.

[0046] In some embodiments, CyC is  (7-oxa-2-azaspiro[3.5]nonan-2-yl), or  (2-oxaspiro[3.5]nonan-7-yl).

[0047] In some embodiments, R^{3a} is independently selected from hydrogen, halogen, cyano, oxo, $-OR^{3b}$, $-NR^{3b}R^{3c}$, $-C(=O)R^{3b}$, $-SO_2R^{3b}$, $-C_{1-6}$alkyl, monocyclic C_{3-6}cycloalkyl, or monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or

oxygen or sulfur heteroatom as ring members, each of said -C_{1-6}alkyl and monocyclic 4 to 9-membered heterocyclyl group is optionally substituted with one or two substituents R^{3e}.

[0048] In some embodiments, cycloalkyl as R^{3a} is C_{3-6}cycloalkyl; more preferably cyclopropyl.

[0049] In some embodiments, heterocyclyl as R^{3a} is 4 to 6-membered heterocyclyl groups containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members.

[0050] In some embodiments, heterocyclyl as R^{3a} is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperzinyl, or morpholinyl.

[0051] In some embodiments, heterocyclyl as R^{3a} is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, or morpholin-4-yl.

[0052] In some embodiments, heterocyclyl as R^{3e} is a monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members.

[0053] In some embodiments, heterocyclyl as R^{3e} is tetrahydro-pyran-4-yl.

[0054] In some embodiments,R^{3a} is -$NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is heterocyclyl.

[0055] In some embodiments, R^{3a} is -$NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is tetrahydro-pyran-4-yl.

[0056] In some embodiments, R^{3a} is -$NR^{3b}R^{3c}$, wherein R^{3b} and R^{3c} are each independently hydrogen or –C_{1-6}alkyl substituted with cycloalkyl, preferably –C_{1-6}alkyl substituted with monocyclic C_{3-6}cycloalkyl.

[0057] In some embodiments, R^{3a} is -OR^{3b} or -SO_2R^{3b}, wherein R^{3b} is hydrogen or C_{1-8}alkyl, preferably methyl.

[0058] In some embodiments, R^{3a} is -COR^{3b}, wherein R^{3b} is hydrogen or C_{1-6}alkyl optionally substituted with -$NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are each independently hydrogen or C_{1-6}alkyl, preferably methyl.

[0059] In some embodiments, two adjacent R^3 on the phenyl ring together with the phenyl ring form indazolyl which is substituted with tetrahydropyranyl.

[0060] In some embodiments, m is 1 and R^3 is selected from the group consisting of:

